BioCryst (BCRX) AI Stock Analysis

• Market Cap: $1.74B
• Dividend Yield: N/A
• Average Volume (3M): 3.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 45.85%
• EPS Growth: 76.36%
• Country: US
• Employees: 580
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 209,920,430
• 10 Day Avg. Volume: 2,003,229
• 30 Day Avg. Volume: 3,034,318
• PEG Ratio: 0.28
• Price to Book (P/B): -3.27
• Price to Sales (P/S): 3.45
• P/FCF Ratio: -29.25
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 4.86
• Enterprise Value/Gross Profit: 5.02
• Enterprise Value/Ebitda: 55.90
• 1Y Price Target: $17.50
• Price Target Upside: 111.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 56 Neutral
• Price Target: $8.50 ▲(2.53% Upside)

BioCryst's strong earnings call and strategic corporate events are major positives, but financial instability and bearish technical indicators weigh down the overall score. Continued focus on profitability and debt management is crucial for future stability.

Positive Factors

Debt Management

The sale of the European Orladeyo business provides a clear line of sight for settling outstanding debt, which had been a concern for some investors.

Market Demand

Increasing demand from patients with normal C1-inhibitor status supports continued revenue growth into the future.

Product Advantage

Orladeyo’s status as the only oral prophylactic therapy for HAE on the market provides a competitive advantage.

Negative Factors

Geographic Revenue Impact

The company announced the sale of their EU franchise, which no longer includes EU sales in peak sales models.

Regulatory Challenges

The FDA extended the PDUFA for the Orladeyo granule formulation in pediatric HAE patients by 3 months, indicating potential regulatory delays.

BioCryst Business Overview & Revenue Model

Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

How the Company Makes Money

BioCryst generates revenue primarily through the sale of its approved products, such as Orladeyo, which contributes to its direct sales revenue. In addition, the company may earn revenue from licensing agreements and collaborations with other pharmaceutical companies, which can include upfront payments, milestone payments upon achieving certain development or sales targets, and royalties on sales of partnered products. The company's ongoing research and development efforts may also lead to additional revenue opportunities through future product launches and potential government grants or partnerships aimed at bringing innovative therapies to market.

BioCryst Financial Statement Overview

Summary

BioCryst has strong revenue growth and gross profit margins, but faces challenges with persistent net losses and negative equity, indicating high financial risk. Improvements in cash flow generation are noted but reliance on external financing remains.

Income Statement

BioCryst shows a positive trend in revenue growth with a significant increase to $503.5M in TTM, up from $450.7M in 2024. Gross profit margin remains strong at approximately 97%, indicating efficient cost management. However, the company continues to report net losses, with a net profit margin of -10.6% in TTM. The EBIT and EBITDA margins have improved but remain low due to ongoing operational challenges.

Balance Sheet

The balance sheet reflects financial instability with negative stockholders' equity, which stands at -$451.9M in TTM, indicating liabilities exceed assets. The debt-to-equity ratio is not meaningful due to negative equity. Return on equity is negative due to consistent net losses. The equity ratio is non-existent, highlighting significant financial leverage and risk.

Cash Flow

Free cash flow improved slightly but remains negative at -$27.3M in TTM. Operating cash flow is also negative, impacting the company’s ability to fund operations internally. The free cash flow to net income ratio indicates challenges in converting earnings to cash, although there is a positive trend in reducing cash flow deficits over time.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	503.49M	450.71M	331.41M	270.83M	157.17M	17.81M
Gross Profit	487.82M	438.44M	325.10M	262.80M	149.13M	16.14M
EBITDA	43.80M	12.81M	-116.33M	-143.85M	-121.74M	-167.56M
Net Income	-53.47M	-88.88M	-226.54M	-247.12M	-184.06M	-182.81M
Balance Sheet
Total Assets	480.05M	490.42M	516.96M	550.00M	588.15M	334.71M
Cash, Cash Equivalents and Short-Term Investments	295.09M	320.85M	388.99M	424.31M	507.60M	300.37M
Total Debt	794.99M	841.42M	848.71M	741.45M	593.24M	279.50M
Total Liabilities	931.97M	966.35M	972.49M	844.60M	695.14M	353.98M
Stockholders Equity	-451.93M	-475.93M	-455.53M	-294.60M	-106.99M	-19.26M
Cash Flow
Free Cash Flow	-27.29M	-53.14M	-97.31M	-163.20M	-144.54M	-137.73M
Operating Cash Flow	-26.25M	-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
Investing Cash Flow	50.93M	52.59M	-131.50M	-128.24M	15.80M	-6.86M
Financing Cash Flow	-4.18M	-5.76M	32.48M	88.03M	359.67M	300.59M

BioCryst Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Negative. The current price of 8.29 is below the 20-day moving average (MA) of 8.38, below the 50-day MA of 8.59, and below the 200-day MA of 8.47, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 43.55 is Neutral, neither overbought nor oversold. The STOCH value of 31.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCRX.

BioCryst Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MNKD	63 Neutral	$1.76B	50.41	-35.00%	―	21.48%	162.30%
AGIO	60 Neutral	$2.28B	3.68	64.05%	―	30.57%	―
ARWR	57 Neutral	$3.55B	―	-34.80%	―	2816.21%	73.33%
KYMR	57 Neutral	$2.91B	―	-33.26%	―	-49.51%	-44.09%
BCRX	56 Neutral	$1.74B	―	18.68%	―	45.85%	76.36%
Sector *	51 Neutral	$7.90B	-0.33	-41.70%	2.23%	23.45%	-1.99%
IRON	43 Neutral	$2.13B	―	-26.36%	―	―	-22.19%

BioCryst Corporate Events

BioCryst’s Chief R&D Officer Resigns Amid CEO Decision

On August 6, 2025, Dr. Helen Thackray announced her resignation as Chief Research and Development Officer of BioCryst Pharmaceuticals, effective September 1, 2025, after not being selected as the next CEO. The company has entered into a Separation Agreement with Dr. Thackray, offering various benefits, and a Consulting Agreement for transition services until the end of 2025, ensuring a smooth transition and continuity in operations.

BioCryst Reports Strong Q2 2025 Financial Performance

In the second quarter of 2025, BioCryst Pharmaceuticals reported a significant financial performance with ORLADEYO net revenue reaching $156.8 million, a 45% increase year-over-year, and an operating profit of $29.8 million, marking a 239% rise. The company also announced plans to retire its remaining term debt through the sale of its European ORLADEYO business, which is expected to further strengthen its financial position. The growth in ORLADEYO’s demand, particularly in the U.S., and the promising pipeline developments, including new drug applications and ongoing trials, highlight BioCryst’s strategic focus on expanding its market presence and delivering value to stakeholders.

BioCryst Announces New President Amid Leadership Change

On July 31, 2025, BioCryst Pharmaceuticals announced the retirement of Jon Stonehouse as President and CEO, effective December 31, 2025, with Charlie Gayer appointed as the new President effective August 1, 2025, and CEO starting January 1, 2026. Gayer, who has been instrumental in the commercial success of ORLADEYO and shaping the company’s business strategy, is expected to continue driving growth and value creation for stakeholders.

BioCryst Appoints New CFO to Drive Growth

On July 7, 2025, BioCryst Pharmaceuticals announced the appointment of Babar Ghias as Chief Financial Officer and Head of Corporate Development. Mr. Ghias brings extensive experience from his previous roles at AvenCell Therapeutics and Paragon Biosciences, where he was instrumental in launching biotechnology companies and raising significant capital. His appointment is expected to bolster BioCryst’s leadership team as the company aims to accelerate growth and enhance value creation. This strategic move is seen as pivotal for BioCryst’s operational excellence and financial discipline, supporting its ambitious growth plans.

BioCryst Sells BioCryst Ireland to Neopharmed Gentili

On June 27, 2025, BioCryst Pharmaceuticals entered into a Stock Purchase Agreement to sell its equity interests in BioCryst Ireland to Neopharmed Gentili S.p.A. for $250 million, with potential additional payments based on revenue milestones. This transaction, expected to close in October 2025, will involve amendments to existing intellectual property agreements and establish BioCryst as the exclusive supplier of ORLADEYO® to the company, impacting BioCryst’s operations and market positioning in Europe.

BioCryst Sells European ORLADEYO Business for $264M

On June 27, 2025, BioCryst Pharmaceuticals announced the sale of its European ORLADEYO business to Neopharmed Gentili for up to $264 million. The transaction will allow BioCryst to eliminate its remaining term debt, saving approximately $70 million in future interest payments, and is expected to leave the company with $700 million in cash by the end of 2027. This strategic move aligns with BioCryst’s goal of enhancing profitability and sustaining growth, while Neopharmed Gentili aims to strengthen its position in the European specialty pharmaceutical market.

FDA Extends BioCryst’s ORLADEYO Review Deadline

On June 23, 2025, the FDA extended the PDUFA goal date for BioCryst‘s new drug application for ORLADEYO® oral granules for pediatric HAE patients aged 2 to 11. This extension, moving the target action date to December 12, 2025, was due to the submission of additional reports and data, which the FDA considered a major amendment requiring a full review.

BioCryst Stockholders Approve Stock Incentive Plan Amendment

On June 11, 2025, George B. Abercrombie announced his retirement from BioCryst‘s Board of Directors, effective at the 2025 Annual Meeting. The company expressed gratitude for his 13 years of service. On June 12, 2025, BioCryst’s stockholders approved an amendment to the Stock Incentive Plan, increasing available shares by 11 million. The meeting also included the election of directors, ratification of Ernst & Young LLP as accountants, and approval of executive compensation.

BioCryst Extends Consulting Agreement with Former CFO

BioCryst Pharmaceuticals extended a Consulting Agreement with its former CFO, Anthony Doyle, to ensure a smooth transition in leadership. The agreement, effective April 9, 2025, and extended on May 31, 2025, will continue on a month-to-month basis after December 31, 2025, providing stability during the CFO transition.